NORTHFIELD, Illinois, May 24, 2026, 12:02 (CDT)
Medline Inc.’s next test comes before the opening bell after a holiday weekend: whether investors keep the stock near a $37 secondary-offering price after selling shareholders upsized the deal to 72.55 million Class A shares, with a 30-day option for underwriters to buy 10.88 million more. Medline said it will not sell shares or receive proceeds, and expects the offering to close on May 28.
Why it matters now is simple. This is not fresh growth capital. It is stock from backers tied to Blackstone, Hellman & Friedman and Abu Dhabi Investment Authority, and it lands less than six months after the medical-supply group’s market debut.
Medline ended Friday at $37.01, down 0.24%, after volume jumped to 43.07 million shares. The stock finished the week 2.3% above the prior Friday close of $36.19, but the path was choppy: up 4.7% Tuesday, down 3.9% Wednesday, then a partial recovery as the offering price came into view.
The calendar adds a wrinkle. Nasdaq says U.S. stock markets are closed on Monday, May 25, for Memorial Day, so the first full market reaction to the finalized resale comes Tuesday.
The broader tape gave Medline some help. The S&P 500 rose 0.4% on Friday and gained 0.9% for the week, the Dow added 2.1% for the week, and the Nasdaq Composite rose 0.5%, as U.S. stocks posted an eighth straight weekly gain.
The sale was larger than first advertised. Medline said on May 20 that the same holder group had begun a 60 million-share offering, with an option for 9 million more; by pricing, the base deal had grown by more than 12 million shares. A secondary offering — a sale by existing holders, not the company — can improve float, meaning the publicly tradable supply of shares, but it can also remind buyers that more sponsor-owned stock may still come.
Medline’s operating story remains solid, but not clean. In first-quarter results released this month, net sales rose 10.7% to $7.4 billion, while net income fell 25.8% to $239 million and adjusted EBITDA — earnings before interest, tax, depreciation and amortization, a common cash-profit measure — dropped 10.6% to $776 million. CEO Jim Boyle said Medline had started 2026 with “strong momentum,” and the company raised its full-year organic sales growth outlook, sales growth from the existing business, to 8.5% to 9.5% while keeping adjusted EBITDA guidance at $3.5 billion to $3.6 billion. Medline Inc.
But the downside case is not far away. Tariffs and higher costs have already hit margins, and Boyle told analysts Medline did not see “much change in utilization” in the first quarter — utilization means how often patients use healthcare services — but that the industry could see softness in the back half of the year if reimbursement cuts or insurance access limit care. Investing.com Nigeria
Competition also matters. Medline sells into the same medical supply and distribution market as McKesson and Cardinal Health, and Reuters has described it as a major maker and distributor of surgical kits, gloves and gowns used in hospitals worldwide. Around the December IPO, Boyle said the listing allowed Medline to “buy down debt and amplify our voice,” while Jeff Zell, senior research analyst at IPO Boutique, told Reuters the company stood apart from many growth listings because it was “profitable, cash-generative, and well understood.” Reuters
For the week ahead, the level to watch is $37. A firm hold above the secondary price would suggest investors can absorb a sizable sponsor exit; a break below it would feed the simpler bear case, that supply is still heavier than demand.
The market will not have long to decide. Trading resumes Tuesday, the offering is due to close Thursday, and Medline’s post-IPO story is moving from debut pop to ordinary public-company tests: margins, debt, tariffs and how much stock large early holders still want to sell.
